Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers

Abstract

Many cancers lack functional expression of the enzyme argininosuccinate synthetase 1 (ASS1) that is necessary for synthesis of L-arginine. These cancers must import arginine for survival and growth, and this reliance can be targeted by arginine-degrading extracellular enzymatic drugs, most commonly PEGylated arginine deiminase. These enzymes can become targets of the immune system, reducing their effectiveness, but PEGylation improves the in vivo stability. Arginine deprivation causes cell death in some cancers, but others gain resistance by expressing ASS1 after a starvation response is induced. Other resistance mechanisms are possible and explored, but these have not been observed specifically in response to arginine deprivation. Future studies, especially focusing on the mechanisms of ASS1 upregulation and metabolic adaptations, may yield insights into preventing or taking advantage of resistance adaptations to make arginine deprivation therapy more effective.

Keywords

PEGylated arginine deiminase / argininosuccinate synthetase 1 / resistance / metabolism / arginine

References

[1] Bean GR,Prudner BC,Yao JC.A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas..Cell Death Dis2016;7:e2406 PMCID:PMC5133958

[2] Kremer JC,Lange SES,Schultze MB.Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers..Cell Rep2017;18:991-1004 PMCID:PMC5840045

[3] Long Y,Wangpaichitr M,Savaraj N.Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction..Mol Cancer Ther2013;12:2581-90 PMCID:PMC3839414

[4] Patel VB,Rajendram R.L-Arginine in Clinical Nutrition.2015;New YorkHumana Press New York

[5] Dillon BJ,Curley SA,Holtsberg FW.Incidence and distribution of argininosuccinate synthetase deficiency in human cancers..Cancer2004;100:826-33

[6] Qiu F,Sui M.Targeting arginine metabolism pathway to treat arginine-dependent cancers..Cancer Lett2015;364:1-7

[7] Qiu F,Liu X,Shen LJ.Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells..Sci Signal2014;7:ra31 PMCID:PMC4229039

[8] Allen MD,Hudson C,Delage B.Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging..Cancer Res2014;74:896-907

[9] Kelly MP,Wu BW,Old LJ.Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase..Br J Cancer2012;106:324-32 PMCID:PMC3261683

[10] Miyamoto T,Saichi N,Hirata M.Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53..Sci Adv2017;3:e1603204 PMCID:PMC5438217

[11] Tissue expression of ASS1 - Summary - The Human Protein Atlas. Available from: https://v15.proteinatlas.org/ENSG00000130707-ASS1/tissue [Last accessed on 14 Aug 2019]

[12] Uhlen M,Hallstrom BM,Oksvold P.Proteomics. Tissue-based map of the human proteome..Science2015;347:1260419

[13] Delage B,Maharaj L,Syed N.Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis..Cell Death Dis2012;3:e342 PMCID:PMC3406582

[14] Huang HY,Wang YH,Fang FM.ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance..Clin Cancer Res2013;19:2861-72

[15] Tsai WB,Lee Sy,Savaraj N.Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4..Mol Cancer Ther2009;8:3223-33 PMCID:PMC2795119

[16] Szlosarek PW,Pallaska A,Smith P.In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion..Clin Cancer Res2006;12:7126-31

[17] Nelson DL.Lehninger principles of biochemistry.2013;New York - BasingstokeFreeman - Macmillan

[18] Wu G.Arginine metabolism: nitric oxide and beyond..Biochem J1998;336:1-17 PMCID:PMC1219836

[19] Mori M.Regulation of nitric oxide production by arginine metabolic enzymes..Biochem Bioph Res Co2000;275:715-9

[20] Rabinovich S,Yizhak K,Silberman A.Diversion of aspartate in ASS1-deficient tumors fosters de novo pyrimidine synthesis..Nature2015;527:379-83 PMCID:PMC4655447

[21] Sullivan LB,Danai LV,Diehl FF.Aspartate is an endogenous metabolic limitation for tumour growth..Nat Cell Biol2018;20:782-8 PMCID:PMC6051729

[22] Garcia-Bermudez J,La K,Fidelin J.Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours..Nat Cell Biol2018;20:775-81 PMCID:PMC6030478

[23] Erez A,Goldman O,Jacob A.Acid-induced downregulation of ASS1 contributes to the maintenance of intracellular pH in cancer..Cancer Res2019;79:518-33 PMCID:PMC6359973

[24] Spinelli JB,Ringel AE,Clish CB.Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass..Science (New York, NY)2017;358:941-6 PMCID:PMC5748897

[25] Sciacovelli M,Johnson TI,da Costa ASH.Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition..Nature2016;537:544-7 PMCID:PMC5136292

[26] Patil M,Babykutty S,Fukumura D.Arginine dependence of tumor cells: targeting a chink in cancer’s armor..Oncogene2016;35:4957-72 PMCID:PMC5457742

[27] Oginsky EL.The arginine dihydrolase system of Streptococcus faecalis. II. Properties of arginine desimidase..J Biol Chem1952;198:799-805

[28] Holtsberg FW,Steiner MR,Clark MA.Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties..J Control Release2002;80:259-71

[29] Przystal JM,Khozoie C,Zeng Q.Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM..Cell Death Dis2018;9:1192 PMCID:PMC6294248

[30] Tsai WB,Long Y,Feun L.Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells..Cancer Res2012;72:2622-33 PMCID:PMC3433038

[31] Locke M,Freitas M,Lattanzio L.Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1..Cell Rep2016;16:1604-13 PMCID:PMC4978703

[32] Land SC.Hypoxia-inducible Factor 1α Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif..J Biol Chem2007;282:20534-43

[33] Sears RC.The life cycle of C-myc: from synthesis to degradation..Cell Cycle (Georgetown, Tex)2004;3:1133-7

[34] Long Y,Chang JT,Wangpaichitr M.Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation..Oncotarget2016;7:82658-70 PMCID:PMC5347722

[35] Tsai WB,Chang JT,Feun LG.Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression..Sci Rep2017;7:10814 PMCID:PMC5589935

[36] Kim RH,Bowles TL,Sutcliffe J.Arginine Deiminase as a Novel Therapy for Prostate Cancer Induces Autophagy and Caspase-Independent Apoptosis..Cancer Res2009;69:700-8 PMCID:PMC2629384

[37] DeVorkin L,Carleton G,Ho C.Autophagy Regulation of Metabolism Is Required for CD8+ T Cell Anti-tumor Immunity..Cell Rep2019;27:502-13.e5

[38] Long Y,Wang D,Savaraj N.Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy..Cancer Lett2017;388:54-63

[39] Prudner BC,Robinson AM,Chang SF.Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors..Clin Cancer Res2019;

[40] Takaku H,Abe SI,Miyazaki K.In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini..Int J Cancer1992;51:244-9

[41] Ensor CM,Bomalaski JS.Pegylated Arginine Deiminase (ADI-SS PEG20,000 mw) Inhibits Human Melanomas and Hepatocellular Carcinomas in Vitro and in Vivo..Cancer Res2002;62:5443-50

[42] Abou-Alfa GK,Ryoo BY,Yen CJ.Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma..Ann Oncol2018;29:1402-8

[43] Tsai HJ,Hung WC,Lin SF.A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients..Sci Rep2017;7:11253 PMCID:PMC5595917

[44] Ott PA,Pandit-Taskar N,Hoffman EW.Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma..Invest New Drugs2013;31:425-34 PMCID:PMC4169197

[45] Beddowes E,Chan PY,Corbacho JG.Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers..J Clin Oncol2017;35:1778-85 PMCID:PMC6141244

[46] Lowery MA,Kelsen DP,Bomalaski JS.A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma..Cancer2017;123:4556-65

[47] Rodriguez PC,Ochoa AC.l-arginine availability regulates T-lymphocyte cell-cycle progression..Blood2007;109:1568-73 PMCID:PMC1794048

[48] Szlosarek P,Sheaff M,Lau K.MA 19.05 Pegylated Arginine Deiminase Potentiates PD-1/PD-L1 Immune Checkpoint Blockade in Malignant Mesothelioma..J Thorac Oncol2017;12:S1884

[49] Brin E,Lu HT,Dai Z.PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration..Oncotarget2017;8:58948-63 PMCID:PMC5601705

[50] Miraki-Moud F,Ariza-McNaughton L,Clear A.Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo..Blood2015;125:4060-8

[51] Prudner BC,Kremer JC,Huang C.Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas..Theranostics2018;8:2107-16 PMCID:PMC5928874

[52] Commisso C,Soydaner-Azeloglu RG,Kamphorst JJ,Grabocka E,Drebin JA,Rabinowitz JD,Vander Heiden MG.Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells..Nature2013;497:633-7 PMCID:PMC3810415

[53] Kamphorst JJ,Commisso C,Lu W.Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein..Cancer Res2015;75:544-53 PMCID:PMC4316379

[54] Palm W,Wright K,Tuveson DA.The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1..Cell2015;162:259-70 PMCID:PMC4506698

[55] Kim SM,Ravi A,Finicle BT.PTEN Deficiency and AMPK Activation Promote Nutrient Scavenging and Anabolism in Prostate Cancer Cells..Cancer Discov2018;8:866-83 PMCID:PMC6030497

[56] Ghoneum M.Phagocytosis of Candida albicans by metastatic and non metastatic human breast cancer cell lines in vitro..Cancer Detect Prev2004;28:17-26

[57] Coopman PJ,Gehlsen KR.Integrin alpha 3 beta 1 participates in the phagocytosis of extracellular matrix molecules by human breast cancer cells..Mol Biol Cell1996;7:1789-804 PMCID:PMC276026

[58] Overholtzer M,Mouneimne G,Schnitt SJ.A Nonapoptotic Cell Death Process, Entosis, that Occurs by Cell-in-Cell Invasion..Cell2007;131:966-79

[59] Ito A,Kataoka TR,Tsubota N.A role for heterologous gap junctions between melanoma and endothelial cells in metastasis..J Clin Invest2000;105:1189-97 PMCID:PMC315440

[60] Zhang ZQ,Wang BJ,Naus CCG.Effective asymmetry in gap junctional intercellular communication between populations of human normal lung fibroblasts and lung carcinoma cells..Carcinogenesis2004;25:473-82

[61] Leithe E,Omori Y.Downregulation of Gap Junctions in Cancer Cells..Crit Rev Oncog2006;12:225-56

[62] Iwamoto S,Downing JR,Campana D.Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase..J Clin Invest2007;117:1049-57 PMCID:PMC1821067